RobertAForbesJr.MD

PubMed

• 22 citations
  Aripiprazole Treatment of Irritability Associated with Autistic Disorder and the Relationship Between Prior Antipsychotic Exposure, Adverse Events, and Weight Change
  Raymond Mankoski, Gwen Stockton, George Manos, S.V. Marler, Robert D. McQuade, Robert A. Forbes, Ronald N. Marcus> ;Journal of Child and Adolescent Psychopharmacology. 2013 Oct 18
• 76 citations
  Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study☆ , ☆☆
  Suresh Mallikaarjun, John M. Kane, Patricia Bricmont, Robert D. McQuade, William H. Carson, Raymond Sanchez, Robert A. Forbes, W. Wolfgang Fleischhacker> ;Schizophrenia Research. 2013 Oct 1
• 19 citations
  Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes
  Christoph U. Correll, Joan Zhao, William H. Carson, R. Marcus, Robert D. McQuade, Robert A. Forbes, Raymond Mankoski> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2013 Jul 1
• 30 citations
  Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
  W. Wolfgang Fleischhacker, Raymond Sanchez, B. Johnson, Na Jin, Robert A. Forbes, Robert D. McQuade, Ross A. Baker, William H. Carson, John M. Kane> ;International Clinical Psychopharmacology. 2013 Apr 1
• 17 citations
  Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder.
  Eric A. Youngstrom, Joan Zhao, Raymond Mankoski, Robert A. Forbes, Ronald M. Marcus, William H. Carson, Robert D. McQuade, Robert L. Findling> ;Journal of Child and Adolescent Psychopharmacology. 2013 Mar 19
• 43 citations
  Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study
  Robert L. Findling, Christoph U. Correll, Margaretta Nyilas, Robert A. Forbes, Robert D. McQuade, N. Jin, Svetlana Ivanova, Raymond Mankoski, William H. Carson, Gabrie...> ;Bipolar Disorders. 2013 Mar 1
• 10 citations
  Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
  Yonghua Jing, Zhenchao Guo, Iftekhar Kalsekar, Robert A. Forbes, Tony Hebden, Michael E. Thase> ;International Clinical Psychopharmacology. 2013 Mar 1
• 9 citations
  Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.
  Anagha Nadkarni, Iftekhar Kalsekar, Min You, Robert A. Forbes, Tony Hebden> ;Clinicoeconomics and Outcomes Research. 2013 Jan 1
• 4 citations
  Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.
  Tanya J. Fabian, Zachary Cain, Diane Ammerman, James M. Eudicone, Yan Tang, Linda Rollin, Robert A. Forbes, Robert M. Berman, Ross A. Baker> ;The Primary Care Companion for CNS Disorders. 2012 Dec 20
• 2 citations
  Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, do...
  David L. Dunner, Kimberly K. Laubmeier, George Manos, Robert A. Forbes, Ross A. Baker, Robert M. Berman> ;The Primary Care Companion for CNS Disorders. 2012 Nov 22
• 6 citations
  Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response.
  Daniel E. Casey, Kimberly K. Laubmeier, S.V. Marler, Robert A. Forbes, Ross A. Baker> ;The Primary Care Companion for CNS Disorders. 2012 May 31
• 139 citations
  Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
  John M. Kane, Raymond Sanchez, Pamela Perry, Na Jin, B. Johnson, Robert A. Forbes, Robert D. McQuade, William H. Carson, W. Wolfgang Fleischhacker> ;The Journal of Clinical Psychiatry. 2012 May 15
• 2 citations
  Impact of cost-sharing on treatment augmentation in patients with depression.
  Teresa B. Gibson, Yonghua Jing, Msw and Jill E. Bagalman, Zhun Cao, John A. Bates, Tony Hebden, Robert A. Forbes, and Jalpa A. Doshi> ;The American Journal of Managed Care. 2012 Jan 16
• 9 citations
  Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
  John A. Bates, Yonghua Jing, Tony Hebden, Robert A. Forbes, Eunice Chang, Michael S. Broder> ;Journal of Medical Economics. 2012 Jan 1
• 13 citations
  Adjunctive aripiprazole for depression: predictive value of early assessment.
  David J. Muzina, Jessie S. Chambers, Trixia Anne Camacho, James M. Eudicone, Robert A. Forbes, Robert M. Berman, Ross A. Baker> ;The American Journal of Managed Care. 2011 Dec 22
• 6 citations
  Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder
  Yonghua Jing, Stephen S. Johnston, Robert Fowler, John A. Bates, Robert A. Forbes, Tony Hebden> ;Journal of Medical Economics. 2011 Nov 13
• 17 citations
  A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.
  Roger S. McIntyre, Susan L. McElroy, James M. Eudicone, Robert A. Forbes, Berit X. Carlson, Ross A. Baker> ;The Primary Care Companion for CNS Disorders. 2011 Nov 3
• 44 citations
  In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
  Yoshihiro Tadori, Robert A. Forbes, Robert D. McQuade, Tetsuro Kikuchi> ;European Journal of Pharmacology. 2011 Oct 15
• 9 citations
  Intent-to-Treat Analysis of Health Care Expenditures of Patients Treated With Atypical Antipsychotics as Adjunctive Therapy in Depression
  Yonghua Jing, Iftekhar Kalsekar, Suellen M. Curkendall, Ginger S. Carls, Erin Bagalman, Robert A. Forbes, Tony Hebden, Michael E. Thase> ;Clinical Therapeutics. 2011 Sep 1
• 52 citations
  Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors
  Yoshihiro Tadori, Robert A. Forbes, Robert D. McQuade, Tetsuro Kikuchi> ;European Journal of Pharmacology. 2011 Sep 1
• 8 citations
  Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
  Raymond Mankoski, Joan Zhao, William H. Carson, Suja Mathew, Robert A. Forbes> ;Journal of Child and Adolescent Psychopharmacology. 2011 Aug 18
• 11 citations
  A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
  Zhenchao Guo, Gilbert L'Italien, Yonghua Jing, Ross A. Baker, Robert A. Forbes, Tony Hebden, Edward Kim> ;Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2011 Jul 1
• 16 citations
  Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy: ...
  Maurizio Fava, Christina Dording, Ross A. Baker, Raymond Mankoski, Quynh-Van Tran, Robert A. Forbes, James M. Eudicone, Randall Owen, Robert M. Berman> ;The Primary Care Companion for CNS Disorders. 2011 Jan 13
• 2 citations
  Non-HDL Cholesterol: A New Endpoint in Cardio-Metabolic Health Monitoring.
  Ross A. Baker, Robert A. Forbes> ;Primary Care Companion to the Journal of Clinical Psychiatry. 2010 Oct 28
• 10 citations
  Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized c...
  Adelaide S. Robb, William H. Carson, Margaretta Nyilas, Mirza Ali, Robert A. Forbes, Taro Iwamoto, Sheila Assunção-Talbott, Richard Whitehead, Andrei Pikalov> ;Journal of Child and Adolescent Psychopharmacology. 2010 Feb 18
• Join now to see all